JSE LIMITED - Dealings in securities by a director, a prescribed officer and the JSE LTIS 2018 Trust

Dealings in securities by a director, a prescribed officer and the JSE LTIS 2018 Trust

JSE LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 2005/022939/06)
Share Code: JSE
ISIN: ZAE000079711
LEI: 213800MZ1VUQEBWRFO39
("JSE")

DEALINGS IN SECURITIES BY A DIRECTOR, A PRESCRIBED OFFICER AND THE JSE LTIS
2018 TRUST

The JSE LTIS 2018 Trust ("Trust") has acquired 42 828 JSE ordinary shares
in the open market to settle awards of forfeitable restricted shares to
participants in the JSE's Long-Term Incentive Scheme ("LTIS 2018").

These JSE ordinary shares were acquired on-market, with prior clearance and
on a direct beneficial basis. The volume-weighted average price ("VWAP")
was R126.4158 per ordinary share. The total transaction value amounted to
R5 414 135. The daily high, low and volume-weighted average price for the
various transactions effected by the Trust were –

 Dates in 2025      Number of       Daily VWAP   Value of daily        Daily          Daily
 that JSE        JSE ordinary           of JSE     transactions      highest         lowest
 ordinary              shares           shares            (ZAR)   price paid     price paid
 shares were         acquired         acquired                    (cents per     (cents per
 acquired                           (cents per                        share)         share)
                                        share)

 28 March               6 043         12661.41       765 129.01        12666          12618
 31 March              36 785         12638.32     4 649 006.01        12700          12558


The requisite approvals have been granted by shareholders at the JSE's
annual general meeting, in respect of the acquisition of JSE ordinary shares
in the open market and in respect of specific financial assistance to the
Trust for the purpose of acquiring these ordinary shares.

ACCEPTANCE OF ALLOCATIONS OF SECURITIES TO A DIRECTOR AND PRESCRIBED OFFICER

Following the acquisition of the JSE ordinary shares by the Trust, the
executive director and the prescribed officer have, on 2 April 2025,
accepted grants of restricted JSE ordinary shares, as reflected below.


 Executive                     Role         Total number    Total Rand value   Nature of
                                           of restricted   of restricted JSE    interest
                                            JSE ordinary     ordinary shares
                                                  shares         awarded and
                                             awarded and            accepted
                                                accepted

 F Suliman              Group CFO &               23 868           3 017 292      Direct
                          Executive                                           beneficial
                           Director
 T Tsoaeli               Prescribed               18 960           2 396 843      Direct
                            Officer                                           beneficial


These ordinary shares are held by the LTIS 2018 participants on a direct
beneficial basis and are restricted until all vesting criteria (as defined)
are fulfilled.
The vesting of these restricted JSE ordinary shares is subject to –

(i)  the JSE achieving specified corporate performance targets over the
     measurement period; and
(ii) the LTIS 2018 participant remaining in the employ of the JSE for the
     vesting term (collectively "the vesting criteria").

To the extent that the vesting criteria are not fulfilled, the share awards
are forfeited.

The restricted shares will vest on 1 March 2028 subject to the vesting
criteria being met.

The individual allocations (grant and acceptance) were approved by the JSE's
Group Remuneration Committee.

Sandton
2 April 2025

Sponsor
RAND MERCHANT BANK (A division of FirstRand Bank Limited)

Date: 02-04-2025 05:05:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.